Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9797359 | 0.86 | GAA (0.46) | CYP2D6CYP2C19GAAKMT2AMEN1 | |
| SCHEMBL4819904 | 0.84 | GAA (0.45) | CYP2D6CYP2C19GAAKMT2AMEN1 | |
| SCHEMBL13681841 | 0.84 | GAA (0.45) | CYP2D6CYP2C19GAAKMT2AMEN1 | |
| SCHEMBL3373145 | 0.84 | GAA (0.45) | CYP2D6CYP2C19GAAKMT2AMEN1 | |
| SCHEMBL16293376 | 0.83 | ACHE (0.48) | CYP2D6CYP2C19MMP8MMP1EPHX1 | |
| SCHEMBL4611409 | 0.82 | SMN1; SMN2 (0.53) | CYP2D6CYP2C19GAAKMT2AMMP8 | |
| SCHEMBL9117583 | 0.82 | GAA (0.46) | CYP2C19GAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL26853493 | 0.81 | GAA (0.43) | CYP2D6CYP2C19GAAKMT2AMEN1 | |
| SCHEMBL7562939 | 0.81 | KMT2A (0.43) | CYP2D6CYP2C19GAAKMT2AMEN1 | |
| SCHEMBL10634574 | 0.81 | ALDH1A1 (0.45) | CYP2D6CYP2C19GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-9132079-B2 | Product for keratin-containing fibers, containing at least a specific copolymer of the N-vinylpyrrolidone and at least a polymer with structural units derived from maleic acid ester | HENKEL AG & CO. KGAA (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140369946-A1 | PRODUCT FOR KERATIN-CONTAINING FIBERS, CONTAINING AT LEAST A SPECIFIC COPOLYMER OF THE N-VINYLPYRROLIDONE AND AT LEAST A POLYMER WITH STRUCUTRAL UNITS DERIVED FROM MALEIC ACID ESTER | HENKEL AG & CO. KGAA (DE) | 2014-12-18 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-7183307-B2 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCROPORATED (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183307-B2 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCROPORATED (US) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CYP2D6 202/4885CYP2C19 388/4885GAA 283/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CYP2D6 497/4885CYP2C19 180/4885GAA 179/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CYP2D6 497/4885CYP2C19 180/4885GAA 179/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CYP2D6 202/4885CYP2C19 388/4885GAA 283/4885 |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | CYP2D6 2976/4885CYP2C19 3803/4885GAA 1029/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | CYP2D6 478/4885CYP2C19 392/4885GAA 433/4885 |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CYP2D6 202/4885CYP2C19 388/4885GAA 283/4885 |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CYP2D6 202/4885CYP2C19 388/4885GAA 283/4885 |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | CYP2D6 1636/4885CYP2C19 2198/4885GAA 361/4885 |
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | CYP2D6 465/4885CYP2C19 712/4885GAA 1558/4885 |
| US-20140369946-A1 | PRODUCT FOR KERATIN-CONTAINING FIBERS, CONTAINING AT LEAST A SPECIFIC COPOLYMER OF THE N-VINYLPYRROLIDONE AND AT LEAST A POLYMER WITH STRUCUTRAL UNITS DERIVED FROM MALEIC ACID ESTER | KRT18, TUBB6, SMC2 | CYP2D6 1963/4885CYP2C19 2061/4885GAA 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.